AMENDMENTS TO THE CLAIMS

- 1. Canceled.
- 2. Canceled.
- 3. (**Currently Amended**) The <u>A</u> compound according to claim 1, represented by the following general formula (I)

wherein R in the general formula (I) is a linear, branched, or cyclic alkyl group having $\frac{2 + 64}{2}$ carbon atoms.

- 4. (**Currently Amended**) The compound according to claim 3[[1]], wherein R in the general formula (I) is a tert-butyl group.
- 5. (**Previously Presented**) A process for producing a compound represented by the following general formula (I):

Wherein R represents a linear, branched, or cyclic alkyl having 2 or more carbon atoms or an aryl group comprising:

- (1) reacting tetrahydropyran-2-ol with (ethoxycarbonylethylidene) triphenylphospholane;
- (2) protecting a free hydroxyl group of the reaction product from (1);
- (3) transforming a hydroxymethyl group of the reaction product from (2) into a formyl group;

(4) reacting the reaction product from (3) with phosphonoacetic acid ester represented by the following general formula (A):

$$(XO)_{2} \xrightarrow{P} CO_{2}R \qquad (A)$$

wherein R and X each represent a linear, branched, or cyclic alkyl or aryl group;

- (5) reacting the reaction product from (4) with a base and acetaldehyde;
- (6) formally dehydrating the reaction product from (5);
- (7) deblocking a protecting group of the reaction product from (6);
- (8) oxidizing the reaction product from (7);
- (9) reacting the reaction product from (8) with phosphonopropionic acid methyl ester represented by the following general formula (B):

$$(XO)_2 \begin{picture}(0,0) \put(0,0){\line(1,0){100}} \put(0,0){\line(1,$$

wherein X is defined as in (4) above;

- (10) reacting the reaction product from (9) with acetonitrile in the presence of a base;
- (11) reacting the reaction product from (10) with propanal represented by the following general formula (C):

wherein Y represents a protecting group of a hydroxyl group;

- (12) epoxidizing the reaction product from (11);
- (13) deblocking a protecting group of the reaction product from (12);
- (14) dehydrating a cyano group from the reaction product from (13); and
- (15) lactamizing the reaction product from (14).
- 6. (**Previously Presented**) A compound represented by the following general formula (III):

$$\begin{array}{c} CH_3 \\ R-O_2C \\ CH_3 \\ \end{array} \begin{array}{c} CN \\ CH_3 \\ \end{array} \begin{array}{c} CN \\ CH_3 \\ \end{array}$$

wherein R represents a linear, branched, or cyclic alkyl or aryl group and Y represents a protecting group of a hydroxyl group.

7. (**Previously Presented**) A process for producing a compound represented by the following general formula (III):

$$CH_3$$
 $R-O_2C$
 CH_3
 CH_3
 CH_3
 CH_3
 CH_3
 CH_3

wherein R represents a linear, branched, or cyclic alkyl or aryl group and Y represents a protecting group of a hydroxyl group, comprising reacting a compound represented by the following general formula (IV):

$$CH_3$$
 $R-O_2C$
 CH_3
 CH_3
 CH_3
 CH_3
 CH_3
 CH_3

wherein R and Y are defined as above for (III), with a peroxide that steroselectively epoxidizes the compound (IV).

8. (**Currently Amended**) A pharmaceutical composition containing the compound according to any one of claims 1 to claim 3 or 4 as an active ingredient and a pharmaceutically acceptable carrier.

9. Canceled

10. (**Previously Presented**) The process according to claim 5, wherein R in the general formula (I) is a linear, branched, or cyclic alkyl group having 2 or more carbon atoms.

Appl. No: 10/516,743

11. (**Currently Amended**) The process according to claim 5, wherein R in the general formula (I) is a linear, branched or <u>eyeloie-cyclic</u> alkyl group having 2 to 6 carbon atoms.

- 12. (**Previously Presented**) The process according to claim 5, wherein R in the general formula (I) is a tert-butyl group.
- 13. (**Previously Presented**) A method for inhibiting growth of neuroblastoma comprising administering an effective amount of the pharmaceutical composition of claim 8 to a patient in need thereof.